COMPARISON OF THE LONG-TERM EFFECTS OF LIRAGLUTIDE AND GLIMEPIRIDE MONOTHERAPY ON BONE MINERAL DENSITY IN PATIENTS WITH TYPE 2 DIABETES Article

Industry Collaboration International Collaboration

cited authors

  • Gilbert, Matthew P., Marre, Michel, Holst, Jens Juul, Garber, Alan, Baeres, Florian M. M., Thomsen, Henrik, Pratley, Richard E.

funding text

  • We acknowledge the important contribution of our friend and colleague Michaela Diamant, who was involved in manuscript preparation and sadly died before this paper was completed. The study (ClinicalTrials.gov NCTC00294723) was funded by Novo Nordisk, the manufacturer of liraglutide. Editorial assistance was provided by Watermeadow Medical, funded by Novo Nordisk.

abstract

  • Objective: Patients with type 2 diabetes have an increased risk of fragility fractures; the cause is unclear but is likely multifactorial. Some diabetes treatments induce bone loss, accentuating underlying skeletal fragility and increasing fracture risk. This subgroup analysis aimed to compare long-term effects of liraglutide and glimepiride on bone mineral density (BMD) in patients with type 2 diabetes. Methods: LEAD-3, a 52-week, double-blind, active-control, phase III, multicenter trial, investigated the efficacy of liraglutide (1.2 and 1.8 mg/day) versus glimepiride monotherapy in type 2 diabetes. A 52-week, open-label extension followed, in which participants remained on randomized therapy. A subgroup of participants underwent BMD measurement by dual-energy X-ray absorptiometry at baseline, 52, and 104 weeks. The main outcome measure was change from baseline in total body BMD at 52 and 104 weeks, assessed by analysis of covariance. Results: A total of 746 patients with type 2 diabetes aged 19 to 79 years were randomized into the main trial. Of these, 61 patients (20 assigned to liraglutide 1.8 mg/day, 23 to liraglutide 1.2 mg/day, 18 to glimepiride 8 mg/day) had BMD measurements. Baseline age, body mass index, diabetes duration, glycated hemoglobin, and total BMD were similar across treatment groups. There was no apparent difference in mean total BMD change from baseline in patients receiving liraglutide 1.8 or 1.2 mg/day or glimepiride 8 mg/day at 52 or 104 weeks. Conclusion: In this small subgroup analysis, liraglutide monotherapy did not negatively affect total BMD in a 2-year prospective study, suggesting it may not exacerbate the consequences of bone fragility.

authors

Publication Date

  • April 1, 2016

webpage

published in

category

start page

  • 406

end page

  • 411

volume

  • 22

issue

  • 4

WoS Citations

  • 13

WoS References

  • 25